Generation and characterization of human U-2 OS cell lines with the CRISPR/Cas9-edited protoporphyrinogen oxidase IX gene.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 10 2022
Historique:
received: 21 03 2022
accepted: 23 09 2022
entrez: 12 10 2022
pubmed: 13 10 2022
medline: 15 10 2022
Statut: epublish

Résumé

In humans, disruptions in the heme biosynthetic pathway are associated with various types of porphyrias, including variegate porphyria that results from the decreased activity of protoporphyrinogen oxidase IX (PPO; E.C.1.3.3.4), the enzyme catalyzing the penultimate step of the heme biosynthesis. Here we report the generation and characterization of human cell lines, in which PPO was inactivated using the CRISPR/Cas9 system. The PPO knock-out (PPO-KO) cell lines are viable with the normal proliferation rate and show massive accumulation of protoporphyrinogen IX, the PPO substrate. Observed low heme levels trigger a decrease in the amount of functional heme containing respiratory complexes III and IV and overall reduced oxygen consumption rates. Untargeted proteomics further revealed dysregulation of 22 cellular proteins, including strong upregulation of 5-aminolevulinic acid synthase, the major regulatory protein of the heme biosynthesis, as well as additional ten targets with unknown association to heme metabolism. Importantly, knock-in of PPO into PPO-KO cells rescued their wild-type phenotype, confirming the specificity of our model. Overall, our model system exploiting a non-erythroid human U-2 OS cell line reveals physiological consequences of the PPO ablation at the cellular level and can serve as a tool to study various aspects of dysregulated heme metabolism associated with variegate porphyria.

Identifiants

pubmed: 36224252
doi: 10.1038/s41598-022-21147-x
pii: 10.1038/s41598-022-21147-x
pmc: PMC9556554
doi:

Substances chimiques

Protoporphyrins 0
Heme 42VZT0U6YR
protoporphyrinogen 7412-77-3
Aminolevulinic Acid 88755TAZ87
Oxidoreductases EC 1.-
Protoporphyrinogen Oxidase EC 1.3.3.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17081

Informations de copyright

© 2022. The Author(s).

Références

Am J Physiol Cell Physiol. 2012 Jun 15;302(12):C1780-5
pubmed: 22496243
Hum Mol Genet. 1995 Dec;4(12):2387-90
pubmed: 8634714
BMC Res Notes. 2020 Feb 4;13(1):57
pubmed: 32019595
Biochem J. 1989 May 15;260(1):231-5
pubmed: 2775186
Chimia (Aarau). 2011;65(12):961-9
pubmed: 22273380
Semin Liver Dis. 1998;18(1):33-41
pubmed: 9516676
Science. 2013 Mar 15;339(6125):1328-1331
pubmed: 23371551
Regul Toxicol Pharmacol. 1989 Oct;10(2):149-59
pubmed: 2813868
Acc Chem Res. 2016 Jun 21;49(6):1104-10
pubmed: 27254265
Biotechniques. 2016 Aug 01;61(2):83-91
pubmed: 27528073
Genomics. 1995 Oct 10;29(3):698-703
pubmed: 8575762
Circulation. 2006 Nov 14;114(20):2178-89
pubmed: 17101869
Biochem Biophys Res Commun. 1982 Apr 14;105(3):985-90
pubmed: 7092911
Cells. 2020 Feb 14;9(2):
pubmed: 32075102
Plant Physiol. 1989 Aug;90(4):1239-42
pubmed: 16666913
Nat Genet. 1996 May;13(1):95-7
pubmed: 8673113
Indian J Gastroenterol. 2016 Nov;35(6):405-418
pubmed: 27796941
Proc Natl Acad Sci U S A. 1970 Oct;67(2):517-22
pubmed: 4108609
Biochemistry. 2017 Apr 4;56(13):1815-1823
pubmed: 28316240
IUBMB Life. 2005 Nov;57(11):749-59
pubmed: 16511968
Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a011676
pubmed: 23471474
Biochem Biophys Res Commun. 1983 Aug 30;115(1):225-31
pubmed: 6615529
Mol Genet Metab. 2019 Nov;128(3):320-331
pubmed: 30594473
Free Radic Biol Med. 2019 Mar;133:88-100
pubmed: 30092350
Int J Mol Sci. 2021 Sep 19;22(18):
pubmed: 34576284
Anal Bioanal Chem. 2017 Dec;409(30):6999-7010
pubmed: 29043383
J Biochem. 2004 Aug;136(2):233-8
pubmed: 15496594
Cancer Genet Cytogenet. 2003 Jul 15;144(2):91-9
pubmed: 12850370
Biochem J. 2005 Mar 1;386(Pt 2):381-6
pubmed: 15482256
Cells. 2020 Feb 29;9(3):
pubmed: 32121449
J Invest Dermatol. 1998 Apr;110(4):452-5
pubmed: 9540991
Plant Physiol. 1991 Sep;97(1):197-203
pubmed: 16668371
Hum Mol Genet. 1996 Mar;5(3):407-10
pubmed: 8852667
Biochim Biophys Acta. 2006 Jul;1763(7):723-36
pubmed: 16839620
Hum Genet. 1981;58(4):425-8
pubmed: 7327566
PLoS One. 2015 Aug 19;10(8):e0135896
pubmed: 26287972
Mol Genet Metab. 2019 Nov;128(3):228-235
pubmed: 31153822
Mol Genet Metab. 2019 Nov;128(3):164-177
pubmed: 31326287
N Engl J Med. 1980 Apr 3;302(14):765-9
pubmed: 7354807
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):67-73
pubmed: 9074790
Clin Exp Dermatol. 1999 Jul;24(4):296-301
pubmed: 10457135
Ciba Found Symp. 1994;180:131-51; discussion 152-5
pubmed: 7842850
Arch Biochem Biophys. 2008 Jun 15;474(2):238-51
pubmed: 18314007
Front Pharmacol. 2014 Apr 08;5:61
pubmed: 24782769
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10553-8
pubmed: 9724741
J Biol Chem. 2013 Apr 26;288(17):11731-40
pubmed: 23467411
Anal Biochem. 2005 Sep 1;344(1):115-21
pubmed: 16039600
Exp Hematol. 2008 Sep;36(9):1132-42
pubmed: 18550261
Hum Mol Genet. 2016 Sep 15;25(18):4062-4079
pubmed: 27466185
Arch Biochem Biophys. 1991 Sep;289(2):387-92
pubmed: 1898078
Biomolecules. 2021 Apr 16;11(4):
pubmed: 33923744
Science. 1993 Jan 22;259(5094):522-5
pubmed: 8424176
Cells. 2021 Feb 10;10(2):
pubmed: 33578848
J Biol Chem. 1995 Apr 7;270(14):8076-80
pubmed: 7713909
Nature. 2008 Jun 19;453(7198):1127-31
pubmed: 18418376
Arch Biochem Biophys. 2000 Dec 15;384(2):280-95
pubmed: 11368315
Mol Ther Nucleic Acids. 2021 May 19;25:207-219
pubmed: 34458006
Cancers (Basel). 2020 Mar 05;12(3):
pubmed: 32150835
Biochim Biophys Acta. 2012 Sep;1823(9):1617-32
pubmed: 22575458
Mol Cell Biol. 2010 Nov;30(22):5318-24
pubmed: 20823265
J Med Genet. 1998 Mar;35(3):244-7
pubmed: 9541112
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Biol Chem. 2011 Jul 29;286(30):26424-30
pubmed: 21659532
Cancer Res. 2019 May 15;79(10):2511-2525
pubmed: 30902795
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cell Mol Biol (Noisy-le-grand). 2002 Feb;48(1):71-8
pubmed: 11929050
Protein Sci. 1996 Jan;5(1):98-105
pubmed: 8771201
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Biochem Biophys Res Commun. 1996 Sep 4;226(1):226-30
pubmed: 8806618
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
Br J Haematol. 2017 Feb;176(4):527-538
pubmed: 27982422
Nat Protoc. 2006;1(1):418-28
pubmed: 17406264

Auteurs

Zora Novakova (Z)

Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic. zora.novakova@ibt.cas.cz.

Mirko Milosevic (M)

Laboratory of Cellular Metabolism, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.
Faculty of Science, Charles University, Vinicna 5, Prague, 12108, Czech Republic.

Zsofia Kutil (Z)

Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Marketa Ondrakova (M)

Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Barbora Havlinova (B)

Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Petr Kasparek (P)

Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Cristian Sandoval-Acuña (C)

Laboratory of Tumour Resistance, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Zuzana Korandova (Z)

Laboratory of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague, 14220, Czech Republic.
First Faculty of Medicine, Charles University, Katerinska 32, Prague, 12108, Czech Republic.

Jaroslav Truksa (J)

Laboratory of Tumour Resistance, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Marek Vrbacky (M)

Laboratory of Bioenergetics, Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, Prague, 14220, Czech Republic.

Jakub Rohlena (J)

Laboratory of Cellular Metabolism, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic.

Cyril Barinka (C)

Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec, 25250, Czech Republic. cyril.barinka@ibt.cas.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH